For nearly twenty years, the only answer India had to bird flu on a poultry farm was to cull the flock. On 20 November 2026, in Bhopal, Union Agriculture Minister Shivraj Singh Chouhan dedicated to the nation what the government calls India's first indigenous vaccine for chickens against avian influenza (H5N1). It was developed by scientists at the ICAR-National Institute of High Security Animal Diseases (NIHSAD) in Bhopal, and it is priced at just ₹1 to ₹2 per dose, so that even a small backyard farmer can afford it. The Minister also announced a new ₹300 crore animal disease research laboratory for the city.
This is a science story, a livestock-economy story and a public-health story at once. This article explains how bird flu works, why a poultry vaccine matters, what the PIB release actually says, and what you should be able to answer about it in an examination.
What the release says
The Press Information Bureau release of 20 November 2026 makes the following points:
- The vaccine is for chickens and targets H5N1, commonly called bird flu. The Minister described it as the world's first vaccine against this particular variant of the virus.
- It was developed by ICAR-NIHSAD, Bhopal. A research team of eight scientists, including the institute's Director, Dr Aniket Sanyal, is named in the release. The Minister said they worked through weekends and followed strict biosafety rules, including sanitising before and after leaving the laboratory.
- The price is ₹1-2 per dose.
- India has seen more than 500 bird flu outbreaks since 2006. The first was reported at Navapur, Maharashtra, in 2006, where about 10 lakh chickens died and many more were culled and buried. About 9 lakh chickens died in 2021 and about 2 lakh in 2026.
- A ₹300 crore laboratory for animal disease research will come up in Bhopal.
The release does not say what type of vaccine it is (live, inactivated or other), which virus clade it targets, or what the trial results are. It also gives no licensing details or date from which the vaccine will be available, so those remain open questions.
Bird flu in plain terms
Avian influenza is a disease caused by influenza A viruses that circulate in wild waterbirds and can spread to domestic poultry. Influenza A viruses are named by two surface proteins:
- H is haemagglutinin, the protein that lets the virus attach to and enter a cell. There are 18 known H types.
- N is neuraminidase, the enzyme that helps newly made virus particles leave the cell. There are 11 known N types.
So H5N1 is a virus carrying haemagglutinin type 5 and neuraminidase type 1. Avian influenza viruses are also grouped by how severe they are in chickens:
| Class | Meaning | Example |
|---|---|---|
| LPAI (low pathogenic) | Mild or no signs in birds | H9N2 |
| HPAI (highly pathogenic) | Sudden death, mortality that can approach 100% in a flock | H5N1 |
Within a subtype, scientists classify viruses into clades, which are branches of the family tree. A vaccine must match the circulating virus closely enough to protect, which is why a foreign vaccine is not an automatic solution for Indian flocks. The release does not name the clade this vaccine targets.
The disease matters beyond the farm. The release notes that the virus can spread to mammals and humans. Human cases are rare and almost always follow close contact with infected birds, but the severity of those cases is the reason health agencies watch every outbreak. That is the logic of One Health, the idea that human, animal and environmental health are linked. Our note on One Health and the national AMR action plan explains the framework.
Why India has culled rather than vaccinated
When a highly pathogenic avian influenza outbreak is confirmed on a farm in India, the standard response has been stamping out: the infected birds, and birds in the surrounding area, are culled and buried, movement is restricted, and the area is put under surveillance. The reasons are straightforward.
- Culling quickly removes the source of infection.
- Many countries that export poultry avoid vaccination, because a vaccinated flock can complicate the testing that proves a country is free of the disease.
- For a long time there was no vaccine made in India for the circulating strain.
Culling works, but it is costly and painful. The Minister's account is a reminder: lakhs of birds destroyed in 2006, 2021 and again in 2026. For a farmer with a few thousand birds, a cull wipes out months of feed and labour. A cheap, locally made vaccine gives an additional tool: it can protect flocks in high-risk areas, reduce the number of birds that must be killed and lower the amount of virus in the environment.
The trade-off is real, and it is worth knowing for the exam. Vaccination does not replace surveillance. A good programme pairs vaccination with testing that can tell vaccinated birds from infected ones (the DIVA principle, short for "differentiating infected from vaccinated animals"), so that hidden infection is not masked. How the new vaccine will be used in practice, whether in targeted zones or more widely, will be decided by the government and will be the thing to watch.
How an inactivated vaccine works
The release does not state the vaccine's type, but inactivated is a favourite term in science papers, and NIHSAD's earlier poultry flu vaccine (H9N2, 2022) was an inactivated one. Vaccines come in broad types:
| Type | What it contains | Notes |
|---|---|---|
| Live attenuated | Weakened, living pathogen | Strong response, small risk of reversion (e.g., oral polio vaccine) |
| Inactivated (killed) | Virus grown in the laboratory and then killed | Cannot cause the disease; usually needs booster doses and an adjuvant |
| Subunit / recombinant | Only a protein or fragment of the pathogen | Very safe; more complex to make |
| mRNA / vector | Instructions for the body to make the antigen | Fast to update |
An inactivated virus cannot replicate, so it cannot give the bird the disease. The immune system still recognises the viral proteins and builds antibodies. The vaccine is usually combined with an adjuvant, a substance that strengthens the response. For the broader science, see our note on vaccination and immunity and the table of viral and bacterial diseases.
There is also a manufacturing point. Poultry vaccines are made in large quantities and sold at very low prices per dose, so a price of ₹1-2 is possible only when the technology moves from the laboratory to industry. ICAR has done this before. In December 2022, its inactivated low pathogenic avian influenza (H9N2) vaccine for chickens, also developed at NIHSAD, was transferred to four commercial companies, with the help of Agrinnovate India Ltd, the technology-transfer company of the Indian Council of Agricultural Research (ICAR). A similar route for the H5N1 vaccine would be the natural next step, although the release does not say so.
The institute behind the vaccine
ICAR-NIHSAD in Bhopal is India's top-security laboratory for animal diseases, and its standing is international.
- It is a BSL-3 (Biosafety Level 3) high-containment facility, built to work safely with dangerous pathogens.
- It is a WOAH reference laboratory for avian influenza. WOAH is the World Organisation for Animal Health, formerly the OIE.
- In June 2025 the WOAH and the FAO recognised it as a Category A Rinderpest Holding Facility, one of only six facilities worldwide entrusted with storing rinderpest virus material. Rinderpest, the "cattle plague", was declared eradicated globally in 2011, so the few remaining stocks are kept under very strict control.
- According to the release, it has earlier developed indigenous vaccines for Gumboro disease (a poultry disease), Brucella abortus S-19 Delta, Classical Swine Fever and African Swine Fever.
Do not confuse this institute with the Indian Veterinary Research Institute (IVRI) at Izatnagar, Uttar Pradesh, another ICAR institute. Scientists at Hisar (the ICAR National Research Centre on Equines) and Izatnagar developed the Lumpi-ProVacInd vaccine for Lumpy Skin Disease, which the Minister recalled. A common question pairs an institute with the disease it works on.
The economic argument
The Minister called livestock "moving ATMs" for farmers, a steady monthly income alongside crop farming. He said animal husbandry contributes 14% to India's GDP and the poultry sector another 1%. Those are the Minister's figures, and official national-accounts estimates are usually quoted differently, as shares of agricultural output, so treat the percentages as his statement rather than a standard statistic.
The disease losses he quoted are easier to use. The release lists average annual losses from:
| Disease | Average annual loss (₹ crore) |
|---|---|
| Foot and Mouth Disease (FMD) | 22,000 |
| Lumpy Skin Disease (LSD) | 20,000 |
| Brucellosis | 9,212 |
| Peste des Petits Ruminants (PPR), in sheep and goats | 4,683 |
Together they add up to about ₹56,000 crore a year. Bird flu is on top of that. The weak link has always been that the farmers who suffer most are small ones, which is why the price per dose is the central selling point.
The government's wider disease-control effort is the National Animal Disease Control Programme (NADCP), launched by the Prime Minister at Mathura. According to the release, 147 crore 16 lakh free vaccine doses against Foot and Mouth Disease have been given under it, and brucellosis is under control. In March 2025, the Union Cabinet approved a revised Livestock Health and Disease Control Programme (LHDCP) with an outlay of ₹3,880 crore for 2024-25 and 2025-26. It brings together NADCP, support to states for animal health and a new Pashu Aushadhi component for cheap generic veterinary medicines. For the farm-economy background, see our note on the agriculture economy.
The Minister recalled that the Lumpy Skin Disease outbreak of 2022 infected about 32.8 lakh animals and killed about 1.86 lakh.
What to watch next
- Licensing and manufacture. Which companies will produce the vaccine, and when will it reach farmers?
- Policy on use. Will vaccination be used in selected high-risk districts, around wetlands and migratory-bird sites, or more widely?
- Surveillance. Vaccination works only if testing continues. Watch for DIVA-compatible tests.
- The ₹300 crore laboratory. Its mandate and timeline were not given.
- Seasonality. Bird flu in India tends to flare in the cooler months, when migratory birds are present, so the coming winter will be the first real test.
🔑 Revision block
The event. On 20 November 2026, Union Agriculture Minister Shivraj Singh Chouhan dedicated India's first indigenous H5N1 vaccine for chickens at Bhopal; a ₹300 crore animal disease research laboratory was also announced for Bhopal.
The vaccine. Developed by ICAR-NIHSAD, Bhopal; the Minister called it the world's first vaccine against this variant; priced at ₹1-2 per dose. The release gives no vaccine type or clade.
The disease. Avian influenza is caused by influenza A; H = haemagglutinin, N = neuraminidase; HPAI (H5N1) versus LPAI (H9N2). First Indian outbreak: Navapur, Maharashtra, 2006; over 500 outbreaks since.
The institute. BSL-3; WOAH reference laboratory for avian influenza; Category A Rinderpest Holding Facility (June 2025, one of six worldwide); earlier vaccines for Gumboro, Brucella S-19 Delta, Classical Swine Fever and African Swine Fever; H9N2 vaccine transferred to industry in December 2022.
Numbers. FMD ₹22,000 crore, LSD ₹20,000 crore, brucellosis ₹9,212 crore, PPR ₹4,683 crore: about ₹56,000 crore a year. 147.16 crore FMD doses given under NADCP. LHDCP: ₹3,880 crore (March 2025).
Key terms. Stamping out; DIVA; adjuvant; One Health; WOAH (formerly OIE).
🎯 Practice MCQs
Q1. The indigenous vaccine dedicated to the nation in Bhopal on 20 November 2026 is meant to protect chickens against which virus subtype?
(a) H1N1
(b) H5N1
(c) H9N2
(d) H3N2
→ (b)
The vaccine targets H5N1 (bird flu). H9N2 is a low pathogenic subtype for which NIHSAD developed a separate vaccine in 2022.
Q2. Which institution developed this vaccine?
(a) National Institute of Virology, Pune
(b) Indian Veterinary Research Institute, Izatnagar
(c) Centre for Cellular and Molecular Biology, Hyderabad
(d) ICAR-National Institute of High Security Animal Diseases, Bhopal
→ (d)
ICAR-NIHSAD at Bhopal is the BSL-3 high-security animal disease institute and a WOAH reference laboratory for avian influenza.
Q3. In the name H5N1, the letters H and N stand for:
(a) Haemagglutinin and neuraminidase
(b) Histamine and nucleotide
(c) Haemoglobin and nitrogenase
(d) Hormone and nuclease
→ (a)
Haemagglutinin helps the virus enter cells; neuraminidase helps new virus particles leave them.
Q4. An inactivated vaccine differs from a live attenuated vaccine because it:
(a) Contains a weakened but living virus
(b) Cannot produce any immune response
(c) Contains virus that has been killed and cannot replicate
(d) Can be made only for bacterial diseases
→ (c)
Killed virus cannot cause the disease but still presents the viral proteins to the immune system, usually with an adjuvant.
Q5. India's first outbreak of highly pathogenic avian influenza, in 2006, was reported from:
(a) Kerala
(b) Maharashtra
(c) Punjab
(d) Assam
→ (b)
The first outbreak was at Navapur in Maharashtra, and about 10 lakh chickens died, according to the Minister.
Q6. Lumpi-ProVacInd, recalled in the release, is an indigenous vaccine against:
(a) Foot and Mouth Disease
(b) Peste des Petits Ruminants
(c) Classical Swine Fever
(d) Lumpy Skin Disease
→ (d)
It was developed by scientists at Hisar and Izatnagar after the 2022 Lumpy Skin Disease outbreak.
Q7. Consider the following statements:
1. Rinderpest was declared eradicated globally in 2011.
2. ICAR-NIHSAD is the only facility in the world that holds rinderpest virus material.
Which of the statements given above is/are correct?
(a) 1 only
(b) 2 only
(c) Both 1 and 2
(d) Neither 1 nor 2
→ (a)
Rinderpest was eradicated in 2011, but NIHSAD is one of only six facilities worldwide recognised as a Category A Rinderpest Holding Facility, so statement 2 is wrong.
Q8. Consider the following statements about the 20 November 2026 announcement:
1. The Minister quoted combined annual losses of about ₹56,000 crore from FMD, Lumpy Skin Disease, brucellosis and PPR.
2. The vaccine is priced at about ₹1-2 per dose.
Which of the statements given above is/are correct?
(a) 1 only
(b) 2 only
(c) Both 1 and 2
(d) Neither 1 nor 2
→ (c)
22,000 + 20,000 + 9,212 + 4,683 is about ₹56,000 crore, and the price per dose was given as ₹1-2.
📋 How this gets asked (PYQ pattern)
Science and technology questions in the CDS paper are mostly concept-led: a news item is used to test a definition you should already know. Expect three kinds of question from this story.
The first is disease and pathogen classification: which diseases are viral, bacterial or protozoan, and what the letters in a virus name mean. Influenza, HIV, dengue and malaria are the usual set, and the examiner likes to mix a viral disease with a bacterial one in the options.
The second is vaccine types and immunity: live attenuated versus inactivated, active versus passive immunity, and the role of antibodies. A typical option swaps a definition one step away from the right one, as in Q4 above.
The third is institutions and "who developed what": which Indian institute is linked to which vaccine or technology. Questions on ICAR institutes, the WOAH and One Health recur, so learn the pairings, not only the headline.
Preparing for CDS? Make a one-page table of disease, causative agent type, vaccine type and the Indian institute linked to it. Revise the basics in our science notes on vaccination and immunity and keep up with the daily CDS current affairs. Learn with experienced faculty in the upcoming Cavalier courses in Delhi.
Source: PIB / Ministry of Agriculture & Farmers Welfare, "India Takes a Historic Leap Towards Self-Reliance: Union Minister Shri Shivraj Singh Chouhan Dedicates Country's First Indigenous H5N1 Bird Flu Vaccine to the Nation in Bhopal", 20 November 2026; PIB, "Transfer of technology 'Inactivated low pathogenic avian influenza (H9N2) vaccine for chickens'", 27 December 2022; PIB, "India Joins Elite Global Group for Rinderpest Virus 'Cattle Plague' Containment", 16 June 2025; PIB, "Cabinet approves Revision of Livestock Health and Disease Control Programme (LHDCP)", 5 March 2025.
✍️ Written by Col D.N. Sharma — Science & general-studies faculty at The Cavalier. Reviewed by the Cavalier Faculty Desk.
